Last reviewed · How we verify
Insulin Regular
Insulin Regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin Regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus, Diabetic ketoacidosis.
At a glance
| Generic name | Insulin Regular |
|---|---|
| Sponsor | The University of Texas Medical Branch, Galveston |
| Drug class | Insulin (short-acting) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Regular is a short-acting human insulin that mimics the body's natural insulin secretion. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in rapid reduction of blood glucose levels, typically within 30 minutes of injection.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Diabetic ketoacidosis
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (NA)
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
- Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise (NA)
- Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Regular CI brief — competitive landscape report
- Insulin Regular updates RSS · CI watch RSS
- The University of Texas Medical Branch, Galveston portfolio CI